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. ~b introduction of the new immunosuppressant ta-
.1 crolimus (FK506, Prograf) in 1989 allowed more 
consistent survival of human intestinal allograft recipients.! 
We report here the first 41 pediatric patients treated with 
this drug, all but the last 7 with follow-up of 1 to 5 years 
(range 0.5 to 5 years). 
Between 1990 to 1995, 41 children received 44 intestinal trans-
plants under tacrolimuslsteroid immunosuppression and included 
the isolated small bowel (S8) (n = 10), liver/small bowel (LS8) 
(n = 27) and multivisceral (MV) (n = 7) allografts. There were 19 
males and 22 females with ages ranging between 0.5 to 18 years 
(mean of 4.2 years). Twenty grafts contained a segment of large 
bowel which was distributed among all three recipient cohorts. 
The last four patients, and one additional patient undergoing 
intestinal rctransplantation were also given unaltered adjuvant 
donor bone marrow. The rational and methods of simultaneous 
bone marrow infusion in solid organ transplantation have been 
reported elsewhere in this issue.2 Immunosuppression, donor and 
recipient surgical procedures and nutritional management were as 
previously described.3 
RESULTS 
Patient and Graft Survivals 
Twenty-four patients are still alive (58.5%). Twenty-three 
of these 24 surviving patients still bear their primary 
allografts. 20 of which are functioning. 
Of the 9 SB graft recipients. eight are alive after 0.5 to 48 
months (88.9%). Two patients lost their grafts to acute 
rejection and developed TPN liver dysfunction. one of 
whom has died of end stage liver disease. One patient 
underwent retransplantation 8 months after primary graft 
enterectomy and is at home off TPN, 8 months posttrans-
plantation. This type of graft succeeded in restoring alimen-
tary function at the highest rate at all follow-up times. with 
the best graft survival (70%). 
The LSB and MY composite grafts shared similar patient 
(50%) and graft survivals (48.2% and 42.9%, respectively). 
Three patients underwent retransplantation: one patient 
received an MY retransplant for chronic rejection. another 
patient received a liver only retransplant after hepatic 
artery thrombosis. and another patient received LSB re-
transplant after acute n:jection and adenovirus hepatitis 
(graft survival '+S.Y'r). Another recipient of an MY graft 
who died was originally a n:cipient of an LSB graft." 
Complications 
Infectious pathogens include bacteria. fungi. and viruses. Of 
the bacterial pathogens. staphylococci and enterococci arc 
common, where as gram-negative rods usually accompanied 
polymicrobial infections. These pathogens may be seen in 
association with intestinal allograft rejection or PTLD. 
Fungal infections in children have been mainly yeast organ-
isms in the abdominal cavity and aspergillus infection of the 
lungs. 
Posttransplant lymphoproliferative diseases (P'ILD) as-
sociated with the Epstein-Barr virus (EBY) has occurred in 
11 children with a mean age of 2.8 years (overall incidence 
of 26.8%); 10 patients presented cytomegalovirus (CMV) 
disease (24%). These episodes are described more exten-
sively elsewhere in this issue.5.6 
A total of 31 surgicaVclinical complications occurred in 
20 recipients (48%). The most common was peritonitis 
which was usually consequent to another technical event 
such as hepatic artery thrombosis, biliary or intestinal 
anastomotic leaks, or intestinal perforation. These compli-
cations were significant contributors to morbidity and mor-
tality. Graft associated vascular complications included 
hepatic artery thrombosis (which was responsible for death 
in 2 recipients), and portal vein stenosis. 
Of the 41 patients, 36 recipients (39 grafts) experienced a 
mean of 2.6 episodes of rejection of the intestinal allograft. 
The incidence of rejection when allograft colon was in-
cluded (90%) was similar to when it was excluded (87.5%). 
The incidence of rejection of the liver allograft in composite 
transplants was: LSB 12 of 27 grafts (44.5%). and MY 3 of 
5 grafts (60%). 
OUTCOME 
Twenty-one (48%) of the 44 grafts were lost by recipient 
death or as the result of graft removal followed by an 
immediate (n = 3) or delayed (n = I) attempt at retrans-
plantation, or return to TPN (n = 2). In five cases the 
failures stemmed from surgical (n = 4), or clinical (n = 1) 
misadventures. Two of these five grafts were functioning at 
or shortly before the time of their loss. The predominant 
factor fo; loss of the remaining 16 grafts were infection (n = 
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3), PTLD (n = 2), rejection (n = 6), and a combination of 
PTLD and rejection (n = 5). 
Total parenteral nutrition (TPN) was discontinued an 
average of 56 days posttransplant. Currently 20 children 
have functioning grafts and are independent of TPN. 
DISCUSSION 
The limitations of intestinal transplantation in children are 
bordered by technicaVclinical, immunologic, and infectious 
barriers. Though patients suffering from intestinal failure 
have a mixed and varied etiologic background, the common 
factor of TPN, with its inherent complications, produces 
clinical scenarios which stipulate severity of illness. These 
factors are significant contributors to outcome, and, thus, 
the development of stringent selection criteria may improve 
results after intestinal transplantation. 
There was no survival difference between the LSB and 
the MV operations. There is, however, a significant survival 
difference when compared to the SB type operation. This 
may reflect the advantage of graft enterectomy and retrans-
plantation. However, it is well known that patients selected 
for isolated intestinal transplantation are generally not 
critically ill, nor are they suffering from failure of any other 
organ systems besides the intestine. 
Infectious complications will generally plague this patient 
population, particularly of viral origin (EBV, CMV). This is 
\-
a result of the nature of the transplant procedure and also 
the immunosuppressive requirements necessary to maintain 
this type of allograft. The development of tools such as the 
use of EBV PCR in the peripheral blood7 may allow for 
early or pre-emptive therapy, thus preventing the end phase 
of these diseases. More experience with the treatment of 
these infections, avoiding concomitant rejection, will likely 
aide in improving survival. 
In spite of the difficulties in management of these com-
plex patients, a small majority is presently enjoying survival 
with normal growth and development. 
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